Breaking News
2 hours ago
Simantini Singh Deo
RxSight appoints Aziz Mottiwala as President and CEO, succeeding Ron Kurtz in planned leadership transition.
Simantini Singh Deo
Angelini Pharma completes Catalyst Pharmaceuticals acquisition to expand its global brain health business.
Simantini Singh Deo
Diagonal Therapeutics doses first patient in Phase 1/2 trial of DIAG723 for hereditary hemorrhagic telangiectasia.
Simantini Singh Deo
Plus Therapeutics partners with Genomic Testing Cooperative to expand its CNSide precision oncology platform.
Simantini Singh Deo